Suresh S. Ramalingam
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
2023/10/20 by Myung-Ju Ahn, Myung‐Ju Ahn, Byoung Chul Cho +34 · 35 citations
Medicine · #CAR-T cell therapy research #Cancer #Cancer Immunotherapy and Biomarkers #Chemotherapy #Clinical endpoint #Clinical trial #Complete response #Confidence interval #Gastroenterology #Immunotherapy #Internal medicine #Lung Cancer Research Studies #Lung cancer #Medicine #Oncology #Surgery
- CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
2018/01/29 by Masao Hashimoto, Alice O. Kamphorst, Se Jin Im +6 · 12 citations
Immunology and Microbiology · Medicine · #Antigen #Biology #Blockade #CAR-T cell therapy research #CD8 #Cancer Immunotherapy and Biomarkers #Cancer research #Cell biology #Cell therapy #Cytotoxic T cell #Effector #Immune Cell Function and Interaction #Immune system #Immunology #In vitro #Internal medicine #Medicine #Receptor #Stem cell #T cell #T-cell receptor
- ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib
2019/12/10 by Yiting Li, Hongjing Zang, Guoqing Qian +4 · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Biochemistry #Biology #Cancer #Cancer research #Cell biology #Cytokine Signaling Pathways and Interactions #Epidermal growth factor #Epidermal growth factor receptor #Erlotinib #Internal medicine #Kinase #Lung Cancer Treatments and Mutations #Lung cancer #MAPK/ERK pathway #Medicine #Melanoma and MAPK Pathways #Mutant #Oncology #Osimertinib #Receptor
- Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
2021/10/18 by Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim +15 · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Treatments and Mutations #Cancer Immunotherapy and Biomarkers #Melanoma and MAPK Pathways #Medicine #Cohort #Internal medicine #Oncology #Retrospective cohort study #Response Evaluation Criteria in Solid Tumors #Chemotherapy #Progressive disease